India, Oct. 12 -- Palisade Bio Inc. (PALI), a clinical-stage biopharmaceutical company, presented new clinical and translational data for PALI-2108 in ulcerative colitis and Crohn's disease at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting.
The five presentations examine the drug's intestinal exposure, biological activity, early clinical responses and potential treatment-response biomarkers.
Ulcerative colitis (UC) and Crohn's disease are chronic inflammatory bowel disease (IBD) that cause inflammation in the digestive tract.
PALI-2108 is an investigational, once-daily oral prodrug designed to activate locally in the terminal ileum and colon. Its active metabolite, PALI-0008, inhibits phosphodiesterase-4 (P...